These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33845947)

  • 21. Individual preferences for COVID-19 vaccination in China.
    Leng A; Maitland E; Wang S; Nicholas S; Liu R; Wang J
    Vaccine; 2021 Jan; 39(2):247-254. PubMed ID: 33328140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
    Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
    Front Immunol; 2021; 12():637982. PubMed ID: 33777030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global North and South must work hand in glove to stop COVID-19.
    Alakija A
    Nat Hum Behav; 2022 Feb; 6(2):171. PubMed ID: 35102356
    [No Abstract]   [Full Text] [Related]  

  • 24. How can countries stretch COVID vaccine supplies? Scientists are divided over dosing strategies.
    Ledford H
    Nature; 2021 Jan; 589(7841):182. PubMed ID: 33437062
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Audio Interview: The Omicron Variant of SARS-CoV-2.
    Rubin EJ; Baden LR; Abdool Karim SS; Morrissey S
    N Engl J Med; 2021 Dec; 385(23):e96. PubMed ID: 34874638
    [No Abstract]   [Full Text] [Related]  

  • 27. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 Vaccine Considerations during Pregnancy and Lactation.
    Blumberg D; Sridhar A; Lakshminrusimha S; Higgins RD; Saade G
    Am J Perinatol; 2021 May; 38(6):523-528. PubMed ID: 33932943
    [No Abstract]   [Full Text] [Related]  

  • 29. Innovation alone won't end COVID-19.
    Amin T
    Nat Hum Behav; 2022 Feb; 6(2):172-173. PubMed ID: 35102360
    [No Abstract]   [Full Text] [Related]  

  • 30. Vaccination and their importance for lung transplant recipients in a COVID-19 world.
    Scharringa S; Hoffman T; van Kessel DA; Rijkers GT
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1413-1425. PubMed ID: 34328054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to redesign COVID vaccines so they protect against variants.
    Callaway E; Ledford H
    Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
    [No Abstract]   [Full Text] [Related]  

  • 32. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Feb; 384(8):e40. PubMed ID: 33626259
    [No Abstract]   [Full Text] [Related]  

  • 34. India's COVID-19 vaccination drive: key challenges and resolutions.
    Choudhary OP; Choudhary P; Singh I
    Lancet Infect Dis; 2021 Nov; 21(11):1483-1484. PubMed ID: 34529961
    [No Abstract]   [Full Text] [Related]  

  • 35. Where did 'weird' Omicron come from?
    Kupferschmidt K
    Science; 2021 Dec; 374(6572):1179. PubMed ID: 34855502
    [No Abstract]   [Full Text] [Related]  

  • 36. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovators target vaccines for variants and shortages in global South.
    Sheridan C
    Nat Biotechnol; 2021 Apr; 39(4):393-396. PubMed ID: 33731936
    [No Abstract]   [Full Text] [Related]  

  • 38. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
    Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A
    Front Immunol; 2021; 12():657711. PubMed ID: 33777055
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies.
    van Oosterhout C; Hall N; Ly H; Tyler KM
    Virulence; 2021 Dec; 12(1):507-508. PubMed ID: 33494661
    [No Abstract]   [Full Text] [Related]  

  • 40. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
    Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
    Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.